H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza revenue guidance for around 10% year-over-year growth ...
Wells Fargo raised the firm’s price target on Arm (ARM) to $185 from $162 and keeps an Overweight rating on the shares. With Arm +40% year-to-date and limited forward estimate changes ahead of ...
Your generous donation will be used to ensure the memory of our Defence Forces and what they have done for us, and what they continue to do for our freedom remains – today and into the future.
Explore the big challenges, opportunities, debates and frameworks for business and human rights. This section contains a selection of key portals curated by our global team.
Your generous donation will be used to ensure the memory of our Defence Forces and what they have done for us, and what they continue to do for our freedom remains – today and into the future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results